HBV mutation literature information.


  Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.
 PMID: 29654894       2018       International journal of antimicrobial agents
Abstract: Despite >50% of M204I/V+-L180M among all HBV resistance cases annually and extensive exposure of patients to lamivudine (LAM), telbivudine (LdT) and adefovir dipivoxil (ADV), ETV resistance also showed a dramatically increased incidence, which rose to 17.1% in 2016.
Abstract: whereas M204I and N236T were more predominant in genotype B than genotype C (40.3% vs.


  Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
 PMID: 29630974       2018       Antiviral research
Abstract: 44.33% (524/1182) rtA181T-positive samples were detected with signature drug-resistant mutations, including 325 with adefovir-resistant mutation rtA181V/N236T, 57 with lamivudine-resistant mutation rtM204V/I, 99 with entecavir-resistant mutation rtM204V/I plus rt184/202/250 substitution(s), and 43 with multidrug-resistant mutation rtA181V/N236T + rtM204V/I +- rt184/202/250 substitution(s).


  Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia.
 PMID: 29408943       2018       PloS one
Result: Among 48 HIV co-infected subjects analyzed, 31.3% (15) of them developed 3TC/ETV resistance at YMDD RT motif due to rtM204V/I+rt
Table: M204I
Discussion: Moreover, with a proportional HBeAg positive and negative status, 29.3% of HIV co-infected patients included in the current study were reported to have 3TC/ETV resistance due to rtM204V/I+rtL180M+rtV173L mutant gene variants.


  Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.
 PMID: 29315352       2018       PloS one
Abstract: The percentage of resistance to Lamivudine was high (40%) and varied according to the M204V/I motif.
Introduction: A high rate (47.4%) of the mutation conferring resistance to Lamivudine (major mutation M204V/I) was registered.
Method: As previously described, we used the Mutation Reporter Tool (MRT) softw


  Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016).
 PMID: 29119303       2018       Virus genes
Abstract: Among the primary NA-resistant mutations, rtM204I (13.44%, 545/4055) occurred more frequently, followed by rtM204V, rtN236T, rtA181T, and rtA181V.
Abstract: For single-base mutations, rtL180M and rtA181V increased gradually during the past seven years, while rtM204I/V and rtN236T decreased after 2015.
Abstract: Moreover, single-base mu


  Hepatitis B Virus preS/S Truncation Mutant rtM204I/sW196* Increases Carcinogenesis through Deregulated HIF1A, MGST2, and TGFbi.
 PMID: 28440785       2018       Antiviral therapy
Abstract: In vitro studies suggest that it might play some replication compensatory role in rtM204I mutants under lamivudine treatment.
Abstract: It is frequently found in combination with rtM204I/V substitution under NUC treatment.
Abstract: RESULTS: Among 261 NUC-treated CHB patients, we found a high detection rate of rtM204I/V substitution (30.7% [80/261]).

Browser Board

 Co-occurred Entities




   Filtrator